Medical device company Medical 21, founded on technology developed at the UI by Prof. Suresh Raghavan, announced that it has landed a $20 million commitment from an individual investor.

Viewpoint Molecular Targeting, UI start-up company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that it has entered into a definitive agreement to merge with Isoray, Inc (NYSE AMERICAN:ISR), a medical technology company and innovator in seed brachytherapy.

Cardio Diagnostics, a pioneering precision cardiovascular testing company founded by UI faculty Dr. Robert Philibert and UI graduate Dr. Meesha Dogan, announced that the U.S. Patent and Trademark Office has issued to the University of Iowa Research Foundation ("UIRF") U.S. Patent No. 11,414,704 titled COMPOSITIONS AND METHODS FOR DETECTING PREDISPOSITION TO CARDIOVASCULAR DISEASE, which is exclusively licensed to the Company from UIRF.